Source: iQoncept / Shutterstock
Fennec Pharmaceuticals (NASDAQ:FENC) has emerged triumphant in its financial report for the first quarter of 2024.
- Fennec Pharmaceuticals surpassed expectations by reporting earnings per share of 41 cents, soaring above the analyst estimate of 26 cents.
- The company achieved remarkable revenue of $25.38 million, a staggering 34.41% increase from the anticipated $18.88 million in revenue.
InvestorPlace Earnings is a project that leverages data to automate the coverage of quarterly earnings reports. The platform swiftly delivers key insights such as earnings per share and revenue, and evaluates a company’s performance against analyst projections.
Article printed from InvestorPlace Media, https://investorplace.com/earning-results/2024/05/fenc-stock-earnings-fennec-pharmaceuticals-for-q1-of-2024/.
©2024 InvestorPlace Media, LLC